WINNIPEG, Manitoba - (January 10, 2003) - Medicure Inc.
(TSX: MPH), a cardiovascular drug discovery and development company
is pleased to announce two significant initiatives in its continuing
effort to strengthen and enhance the Company's corporate image and
the relationships with shareholders, potential investors, business
partners and the larger communities in which it operates.
Effective December 1, 2002, Medicure hired Don Bain as Director
of Investor Relations, to oversee the Company's Investor Relations
and Corporate Communications initiatives, and effective today, Medicure
has launched its newly revamped and upgraded website - www.medicureinc.com
Mr. Bain is fully committed to work implementing a very strong
and proactive Investor Relations and Corporate Communications Program
on behalf of Medicure, including developing and maintaining strong
relations with the Company's shareholders, the financial community
and the business and trade media.
Mr. Bain has many years' experience in Investor Relations, Financial
and Corporate Communications. His extensive background includes
nearly four years as Director of Communications and Investor Relations
at CanWest Global Communications Corp. (TSX: CGS.A and NYSE: CWG),
operating his own Investor Relations and Communications firm in
Winnipeg, and holding the position of Vice-President, Investor Relations
and Corporate Communications at a Toronto-based consulting firm.
During his years as an Investor Relations and Communications consultant,
Bain has worked with publicly traded and privately-held companies
encompassing a variety of industry sectors including, biotech, oil
and gas, retail, manufacturing, real estate, high tech and printing.
Commenting on the appointment, Medicure Chairman and Chief Executive
Officer, Albert D. Friesen, PhD, said: "We are delighted to
have someone with Don's background and experience join Medicure.
He will play an integral role in further developing the important
area of Investor Relations and implementing some key initiatives
on our behalf."
Bain stated that he was excited about the opportunity and the outstanding
upside that Medicure presents: "It is clear that Medicure is
rapidly becoming recognized as a 'major player' in the biotech and
life sciences sector.
"I am looking forward to working with the Medicure team in
developing and implementing, a comprehensive and effective Investor
Relations, Public Relations and corporate Communications strategy
that will raise Medicure's profile with the investment community,
and fully inform potential investors of the Company's many investment
strengths," he added.
Medicure's revitalization and enhancement of its corporate website
represents another major step in the Company's efforts to further
enhance shareholder communications and augment its position in the
biotech industry. The new website has been designed to provide the
latest and most detailed information about the Company, its current
and future initiatives, background on key members of the management
team the Board of Directors and the Scientific Advisory Board and
other related investor information.
The new website features an easy-to-read style, upgraded graphics
and current stock and share price information. Specific highlights
include:
· An enhanced section devoted to existing and potential investors,
including stock information, regulatory filings, and investor presentations
and conference calls;
· Easy-to-understand technical information regarding the
Company's research projects, clinical progress and technology platform;
· Detailed information about the Company's lead product,
MC-1, clinical trial results and the Drug Development Program.
"Medicure has always made it a priority to build and maintain
strong personal and professional relationships with the Company's
shareholders, the financial sector, strategic partners, key media
contacts and members of the community," said Dr. Friesen. "Our
new website is an excellent source of current information about
our company, as well as a showcase of our achievements. The new
website does not replace the need, and more importantly, our desire
to maintain one-on-one contact with our stakeholders. Rather, we
see the site complementing our overall IR activities and performing
the vital function of enabling immediate access to, and transfer
of, a broad range of important information about Medicure."
About Medicure Inc.
Medicure Inc. is a cardiovascular drug discovery and development
Company focused on developing effective therapeutics for unmet needs
in the field of cardiovascular medicine including the prevention
and treatment of ischemia, ischemic reperfusion injury, and stroke.
This press release contains forward-looking statements that
involve risks, which may cause actual results to differ materially
from the statements made, and accordingly may be deemed to be forward-looking
statements made pursuant to the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995. The forward-looking statements
are made as of the date hereof, and the Company disclaims any intention
and has no obligation or responsibility to update or revise any
forward-looking statements, whether as a result of new information,
future events, or otherwise.
Back to 2003 News Archives
